Form 4: Relay Therapeutics CEO Granted 1.45M Stock Options

Relay Therapeutics' President and CEO, Sanjiv Patel, was granted 1.45 million stock options with an exercise price of $7.94, vesting quarterly over four years.

Summary

• Sanjiv Patel, President and CEO of Relay Therapeutics, Inc. (RLAY), was granted 1,450,000 stock options.
• The options have an exercise price of $7.94 per share.
• The grant date for these options is January 13, 2026.
• The options will vest in sixteen equal quarterly installments starting after January 13, 2026.
• Vesting is contingent upon Mr. Patel's continued service with the company.
• The options have an expiration date of January 12, 2036.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal for aligning interests and retention, but it's a standard compensation event rather than a groundbreaking operational or financial announcement. The long vesting period indicates a commitment to long-term performance.

Positives

• Granting a significant number of stock options to the CEO aligns management's interests with long-term shareholder value.
• The vesting schedule encourages long-term retention of key leadership.

Negatives

• Potential dilution for existing shareholders if all options are exercised in the future.
• The exercise price of $7.94 sets a benchmark for future stock performance that must be exceeded for the options to be 'in the money'.

Risks

• The value of the options is dependent on the future stock price of Relay Therapeutics exceeding the exercise price of $7.94.
• If the reporting person's service with the Issuer ceases, unvested options will be forfeited.

Future Outlook

The stock option grant is a long-term incentive, aligning the CEO's future compensation with the company's stock performance over the next decade, subject to continued service and market conditions.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology and pharmaceutical industries, used to attract, retain, and incentivize key leadership by linking their financial success to the company's long-term growth and stock performance.

Related Party Transactions

• The stock option grant to President and CEO Sanjiv Patel is a related party transaction, as it involves compensation to an executive officer.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also potential for increased shareholder value if the options incentivize strong company performance.
• Employees: May signal stability and confidence in leadership.

Next Steps

• Continued service of Sanjiv Patel with Relay Therapeutics for the options to vest.
• Quarterly vesting of 1/16th of the options after January 13, 2026.

Key Dates

Recommendation

This Form 4 reports a routine executive compensation event (stock option grant) and does not contain information that would fundamentally alter the investment thesis for Relay Therapeutics. While it aligns management incentives, it's not a catalyst for a 'buy' or 'sell' recommendation on its own. Investors should 'hold' and evaluate the company based on its core business performance, clinical trial results, and financial health.

Keywords

Relay Therapeutics, RLAY, Sanjiv Patel, Stock Option, Insider Transaction, CEO Compensation, Equity Grant, Form 4, Biotechnology, Pharmaceuticals